Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
AcelRx's DSUVIA(TM) Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical, today announced its clinical data presentation on the safety and efficacy of DSUVIA(TM)(sufentanil sublingual tablet),...

ACRX : 2.00 (+14.29%)
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AcelRx Pharmaceuticals, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company")...

ACRX : 2.00 (+14.29%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX

NEW YORK , Oct. 16, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).   Such investors...

ACRX : 2.00 (+14.29%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX

Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at...

ACRX : 2.00 (+14.29%)
AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge

AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.

LGND : 143.93 (+0.40%)
ACRX : 2.00 (+14.29%)
ADAP : 7.15 (+0.70%)
ADRO : 9.20 (-0.27%)
Today's Research Reports on Trending Tickers: AcelRx Pharmaceuticals and NanoString Technologies

NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Major Indexes pulled back on Thursday as investors digested earnings from JPMorgan Chase and Citigroup. The Dow Jones Industrial Average declined 0.14 percent...

ACRX : 2.00 (+14.29%)
NSTG : 10.23 (-2.85%)
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

AERI : 65.10 (+0.39%)
ACRX : 2.00 (+14.29%)
MRK : 63.88 (+0.20%)
LLY : 87.23 (+1.01%)
AGN : 188.28 (-0.52%)
PFE : 36.42 (+0.50%)
BMY : 64.42 (-0.39%)
AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA(TM) NDA

REDWOOD CITY, Calif., Oct. 12, 2017 /PRNewswire/-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response Letter...

ACRX : 2.00 (+14.29%)
AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA

REDWOOD CITY, Calif. , Oct. 12, 2017 /PRNewswire/-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response...

ACRX : 2.00 (+14.29%)
Dow Returns to All-Time Highs

Dow Returns to All-Time Highs

CORT : 18.39 (+0.49%)
TX : 31.82 (+2.25%)
COP : 50.25 (+1.09%)
ACRX : 2.00 (+14.29%)
ALR : 50.99 (unch)
DGI : 34.40 (+0.73%)
BBRY : 11.57 (+0.70%)
LBTYA : 31.63 (-0.35%)
Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D., as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D., to President and Founder

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for diabetic retinopathy and other ocular diseases, announced today...

DRNA : 5.51 (+4.95%)
ACRX : 2.00 (+14.29%)
ARPO : 5.9500 (-0.83%)
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher

AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.

ACRX : 2.00 (+14.29%)
MEIP : 2.68 (+2.29%)
3 Biotech and Pharma Stocks with Key FDA Catalysts this October

Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.

PTCT : 17.79 (+0.68%)
AERI : 65.10 (+0.39%)
ACRX : 2.00 (+14.29%)
JNJ : 142.40 (+0.25%)
TSRO : 116.40 (+0.77%)
FLXN : 23.15 (-2.44%)
ALXN : 139.02 (-1.03%)
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options

Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.

ACRX : 2.00 (+14.29%)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

PALM BEACH, Florida, September 26, 2017 /PRNewswire/ --

ACRX : 2.00 (+14.29%)
BCRX : 4.80 (-5.88%)
NVAX : 1.05 (-0.94%)
MRNS : 5.30 (+3.72%)
MBRX : 2.18 (-1.36%)
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals

One attractive position with regards to the biotech industry is that there are practically always a few industry leaders on weekly basis that are achieving new milestones and accomplishing key developments...

ACRX : 2.00 (+14.29%)
BCRX : 4.80 (-5.88%)
NVAX : 1.05 (-0.94%)
MRNS : 5.30 (+3.72%)
MBRX : 2.18 (-1.36%)
Today's Research Reports on Trending Tickers: AcelRx Pharmaceuticals and BioTelemetry

NEW YORK, NY / ACCESSWIRE / September 26, 2017 / U.S. markets dropped Monday as geopolitical tensions between the U.S. and North Korea grew and as technology stocks slumped. The Dow Jones Industrial Average...

AAPL : 156.25 (+0.17%)
ACRX : 2.00 (+14.29%)
BEAT : 31.15 (+0.16%)
Today's Research Report Coverage on Medical Equipment Stocks -- AcelRx Pharma, GenMark Diagnostics, ViewRay, and Nevro

If you want a Stock Review on ACRX, GNMK, VRAY, or NVRO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com focuses on the...

NVRO : 91.49 (+0.43%)
GNMK : 7.92 (+1.02%)
ACRX : 2.00 (+14.29%)
VRAY : 6.70 (+5.68%)
AcelRx Upcoming FDA Review, Analyst Target Price and Pipeline Review

NEW YORK, NY / ACCESSWIRE / September 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

ACRX : 2.00 (+14.29%)
AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe...

ACRX : 2.00 (+14.29%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 best NASDAQ 100 stocks that had the highest return in the past year, had consistent price appreciation and still looked like they had room to go.
AMAT +0.76 , NVDA -0.90 , ADSK +1.52 , MU +0.19 , LRCX +4.36
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.21%) this morning are up +0.23% at a new record high on optimism that the Trump administration will be able to enact its tax reform plans after the Senate adopted a fiscal 2018 budget... Read More

Chart of the Day

Chart of the Day

LimeLight Networks (LLNW) is the Barchart Chart of the Day.  The Internet company has a Trend Spotter buy signal, a Weighted Alpha of 18.33+ and gained 149.71% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended Friday with most contracts 3 1/2 to 4 1/2 cents lower. The USDA announced private export sales of 125,000 MT of corn to Unknown Destinations, with an additional 120,000 MT to Spain for 17/18 delivery through their daily reporting s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart